Related Experiment Video
Updated: Jan 13, 2026
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Optimized Lipid Nanoparticle-Mediated mRNA Co-Delivery of SOX5/SOX9 Enables Synergistic Senescence Reversal for
Yang Yu1, Zhongyin Ji1, Hongjun Xu1
1Department of Orthopedic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People's Republic of China.
Background:
Chondrocyte senescence significantly impairs extracellular matrix (ECM) synthesis and accelerates cartilage degradation, driving osteoarthritis (OA) progression. Although gene therapies targeting senescent chondrocytes are promising for OA, developing strategies that simultaneously rejuvenate cartilage function and precisely modulate the inflammatory microenvironment remains challenging.
Methods:
We developed an optimized lipid nanoparticle (LNP)-based delivery platform for the efficient co-delivery of transcription factors SOX5 and SOX9 mRNAs into chondrocytes. The physicochemical properties and biosafety of the formulations were systematically characterized. Additionally, the therapeutic efficacy of these formulations was evaluated in senescent chondrocyte cultures and an ACLT-induced osteoarthritis (OA) rat model.
Results:
The synergistic action of SOX5 and SOX9 markedly enhanced anabolic signaling, promoting synthesis of critical cartilage ECM components (type II collagen and aggrecan). The combination also reduced inflammation-mediated matrix degradation in vitro and in vivo. In a rat OA model, this optimized LNP-mediated co-delivery substantially improved cartilage regeneration, suppressed joint inflammation, and restored joint function compared to single-gene treatment or untreated controls.
Conclusion:
This work provides an advanced, synergistic mRNA therapeutic approach employing optimized LNPs to alleviate chondrocyte senescence and stimulate cartilage regeneration, representing a promising strategy for OA intervention.
Insights
This study developed a novel mRNA therapy using lipid nanoparticles (LNPs) to deliver SOX5 and SOX9. This approach rejuvenates cartilage cells and reduces inflammation, offering a promising treatment for osteoarthritis (OA).
Area of Science:
- Biomedical Engineering
- Regenerative Medicine
- Molecular Therapy
Background:
- Chondrocyte senescence drives osteoarthritis (OA) by impairing extracellular matrix (ECM) synthesis and accelerating cartilage degradation.
- Current gene therapies for OA face challenges in simultaneously restoring cartilage function and managing the inflammatory microenvironment.
Purpose of the Study:
- To develop an optimized lipid nanoparticle (LNP) delivery platform for co-delivering SOX5 and SOX9 mRNAs into chondrocytes.
- To evaluate the therapeutic efficacy of this approach in senescent chondrocytes and an OA rat model.
Main Methods:
- Formulation of optimized LNPs for efficient mRNA co-delivery.
- Systematic characterization of LNP physicochemical properties and biosafety.
- In vitro evaluation in senescent chondrocyte cultures and in vivo assessment in an ACLT-induced OA rat model.
Main Results:
- Synergistic SOX5 and SOX9 delivery enhanced anabolic signaling and ECM component synthesis (type II collagen, aggrecan).
- Reduced inflammation-mediated matrix degradation in vitro and in vivo.
- Improved cartilage regeneration, suppressed joint inflammation, and restored joint function in a rat OA model.
Conclusions:
- Optimized LNPs enable synergistic mRNA therapy for chondrocyte senescence and cartilage regeneration.
- This approach represents a promising strategy for osteoarthritis intervention.
- Co-delivery of SOX5 and SOX9 mRNAs via LNPs alleviates OA progression.
